Thomas Ollila

26PUBLICATIONS
128CO-AUTHORS
Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Cancer therapy (excl. chemotherapy and radiation therapy)Haematological tumoursAutoimmunityPredictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (26)

|Sep 24, 2026
Risk factors for CRS and ICANS with Bispecific Antibodies for Aggressive Lymphomas.

|Sep 10, 2026
Peripheral CD8⁺ T-cell clonality and NK-cell expansion mark early response to mosunetuzumab in indolent B-cell lymphoma.

|Apr 21, 2026
Mosunetuzumab plus polatuzumab vedotin for relapsed/refractory MCL after BTK inhibitor therapy: a phase 2 study.

|Feb 26, 2026
Real-world outcomes and toxicities of CAR-T in relapsed/refractory follicular lymphoma: a multicenter cohort study.

John Sharp, Paolo Strati, Subodh Bhatta

|Jan 06, 2026
Treatment-related outcomes and patterns of relapse in secondary CNS involvement by large B-cell lymphoma.

Juan Pablo Alderuccio, Diva Baggio, Sunwoo Han

|Nov 07, 2025
Outcomes for CART as 2L vs 3L vs 4L or beyond in aggressive B-cell lymphoma: real-world evidence from the ABC Consortium.

John S Wang, Brandon L Ellsworth, Megan Melody

Pageof 5

Frequent Collaborators

12 joint publications

Narendranath Epperla

11 joint publications

Reem Karmali

9 joint publications

Geoffrey Shouse

8 joint publications

Adam J Olszewski